Abstract 111P
Background
In present time, neoadjuvant chemoradiotherapy for distal rectal cancer is part of clinical guidelines in Europe and the USA. According to the literature, there are no unified standards for upper rectal cancer.
Methods
The study included data from patients over 18 years old, with histologically proven adenocarcinoma with TNM stage T2-4aN0-2M0 and tumour location in the upper part of the rectum (10-15 sm). In the main group (A), preoperative chemoradiotherapy was performed: short-course radiotherapy (5x5 Gy), with capecitabine 2000 mg/m2 × 2 times for 14 days, followed by surgical treatment. In the control group (B) only surgical treatment was performed - partial or total mesorectumectomy.
Results
From January 2004 to December 2014, 226 (99.6%) underwent surgical treatment. The incidence of postoperative complications byClavien-Dindo scale was:group A - 17 (16.5%) and group B - 11 (8.9%). Local recurrences in group A occurred in 1 patient (1.2%), in group B - in 3 (2.5%) patients (p = 0.413). Distant metastases in group A developed in 10 (10.2%) patients, in group B -15 (12.6%) patients (p = 0.581). Overall survival was in group A - 90.6%, recurrence-free - 89.6%; in group B - 82.8% and 81.9%, respectively (p = 0.46). Multivariate analysis showed that the affected regional lymph nodes were the main predictor of poor prognosis (p = 0.001, OR = 0.094, CI = 0.035-0.250) and significantly reduced the 5-year disease-free survival rate (p = 0.001, OR = 4.213, CI = 2.010-8.830).
Conclusions
The results of the study showed that neoadjuvant chemoradiotherapy in comparison with the surgical method does not have an advantage for patients with upper rectum cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Jasur Madyarov.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
74TiP - Phase I study of BI 836880, a VEGF/Ang2-blocking nanobody®, as monotherapy and in combination with BI 754091, an anti-PD-1 antibody, in Japanese patients (pts) with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
75P - A parallel deep learning network framework for whole-body bone scan image analysis
Presenter: Xiaorong Pu
Session: Poster display session
Resources:
Abstract
76P - Perception and satisfaction of cancer patients in clinical trials
Presenter: Jukyung Jeon
Session: Poster display session
Resources:
Abstract
77P - A prognostic nomogram for the prediction of neuroblastoma
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
80P - The clinical usefulness of a new fat-dissociation method to detect lymph nodes from surgically resected specimen in colorectal cancer: Prospective randomized study
Presenter: Shiki Fujino
Session: Poster display session
Resources:
Abstract
81P - Concurrent or consolidation chemotherapy during radiation as neoadjuvant treatment for locally advanced rectal cancer: A propensity score analysis from two prospective study
Presenter: JianWei Zhang
Session: Poster display session
Resources:
Abstract
82P - Body mass index, tumour location, and colorectal cancer survival
Presenter: Dake Chu
Session: Poster display session
Resources:
Abstract
83P - Helicobacter bilis may play a role in the carcinogenesis of colitis associated colon cancer correlating to increased number of CD4+CD45RB+ T cells
Presenter: Xiangsheng Fu
Session: Poster display session
Resources:
Abstract
84P - Comprehensive evaluation of relapse risk (CERR) score for colorectal liver metastases development and validation
Presenter: Jianmin Xu
Session: Poster display session
Resources:
Abstract
85P - Which is the best partner for capecitabine-based neoadjuvant chemoradiotherapy in locally advanced rectal cancer? A retrospective analysis of a comprehensive cancer center
Presenter: Jingwen Wang
Session: Poster display session
Resources:
Abstract